Corpus Intelligence IC Memo — NEMOURS CHILDRENS HOSPITAL 2026-04-26 09:32 UTC
IC Memo — NEMOURS CHILDRENS HOSPITAL
Investment Committee Memorandum | FL | 130 beds | Grade C | EBITDA uplift $19.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NEMOURS CHILDRENS HOSPITAL

CCN 103304 | ORANGE, FL | 130 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NEMOURS CHILDRENS HOSPITAL is a 130-bed safety-net/medicaid heavy in ORANGE, FL with $268.7M in net patient revenue and a -10.2% operating margin. The hospital serves a payer mix of 0.4% Medicare, 72.6% Medicaid, and 27.0% commercial.

Thesis: Undervalued. Our ML models identify $19.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -10.2% to -2.8% (+736bps).

Net Revenue HCRIS$268.7M
Current EBITDA COMPUTED$-27.3M
Operating Margin COMPUTED-10.2%
Occupancy HCRIS57.4%
Revenue / Bed COMPUTED$2.1M
Net-to-Gross HCRIS29.9%
Distress Probability ML61.0%

2. Market Context & Competitive Position

261
FL Hospitals
3.2%
State Median Margin
125
Comparable Hospitals

FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of -10.2% places it below the state median. Among 125 size-comparable peers (65-260 beds), the median margin is 5.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (65-260), prioritizing same-state peers. 125 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NEMOURS CHILDRENS HOSPITAL (Target)FL130$268.7M-10.2%
MOFFITT CANCER CENTERFL218$1.91B16.0%
NICKLAUS CHILDRENS HOSPITALFL259$769.3M5.5%
JOHNS HOPKINS ALL CHILDRENS HOFL259$584.5M-10.3%
CCF HOSPITAL - WESTONFL258$465.4M-3.8%
LARGO MEDICAL CENTERFL245$386.4M24.1%
PHYSICIANS REGIONAL MEDICAL CEFL259$378.5M12.6%
WEST KENDALL BAPTIST HOSPITALFL127$361.6M18.5%
HCA FL FT WALTON-DESTIN HOSPFL231$361.3M38.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.6M+210bp18mo
Cost to Collect4.5%2.5%$5.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.3M+122bp9mo
Clean Claim Rate88.0%96.0%$172K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.6M
Cost to Collect
$5.4M
Denial Rate Reduction
$5.3M
A/R Days Reduction
$3.3M
Clean Claim Rate
$172K
Total EBITDA Uplift$19.8M
Current EBITDA$-27.3M
+ RCM Uplift+$19.8M
Pro Forma EBITDA$-7.5M
Current Margin-10.2%
Pro Forma Margin-2.8%
WC Released (1x)$10.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-42.0M$17.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-42.0M$5.7M0.00x-100.0%
Bull Case9.0x11.0x$-37.8M$57.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-37.8M$51.4M0.00x-100.0%
Bear Case11.0x10.0x$-46.2M$-67.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-46.2M$-89.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (72.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 61.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 125 hospitals with 65-260 beds
  • Same-state prioritization (n=126)
  • Comp margins: P25=-5.2% / P50=5.0% / P75=15.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.